yahoo_financeOriginal article
Kailera Says Oral Small Molecule KAI-7535 Achieves Up to 11% Weight Loss in Phase 3 Trial
Phase 3positiveKAI-7535Positive
AI Analysis
Summary
Kailera announced positive Phase 3 trial results for oral small molecule KAI-7535, demonstrating weight loss efficacy of up to 11%.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Achieved up to 11% weight loss
Importance:7/10
Sentiment:
0.70
Phase 3 dataweight lossoral small moleculepositive results
Related Companies
Read the original article
Published by yahoo_finance on July 7, 2026 12:08 PM